EDF Ventures

BeZero Carbon is a global rating agency focused on the voluntary carbon market. The firm specializes in providing independent, risk-based, project-level carbon ratings, which are critical for organizations seeking to invest in carbon projects aimed at combating climate change. By delivering informed assessments, BeZero Carbon equips leading organizations with the necessary knowledge and tools to make more effective climate-related decisions. The company's overarching goal is to enhance investment in environmental markets, thereby contributing to a sustainable future.

DataBank Holdings, Ltd. is a data center and co-location company headquartered in Dallas, Texas, with additional facilities in the Dallas/Fort Worth area, Minneapolis/St. Paul, Eagan, Kansas City, and Atlanta. Founded in 2004, DataBank provides a comprehensive array of services, including co-location solutions that ensure security, power configurations, and cooling. The company also offers managed services such as cloud computing, virtual hosting, network connectivity, and security, along with consulting services that encompass design and implementation, migration, and continuity planning. DataBank emphasizes compliance with various industry standards, including those for payment card security and health data protection. Catering to a diverse clientele across sectors like healthcare, finance, gaming, and hospitality, DataBank is committed to optimizing IT environments and ensuring data availability for enterprises.

IntelePeer is a communications automation platform that utilizes generative AI to enhance customer interactions for businesses. By offering a cloud-based Communications Platform as a Service (CPaaS), the company provides on-demand IP communications and SIP trunking services tailored for enterprises. IntelePeer's platform integrates seamlessly with existing systems, allowing businesses to streamline their communication processes across multiple channels. Its focus on automation not only reduces operational costs but also improves customer experience by delivering efficient and effective communication solutions. The incorporation of AI and analytics further enhances the platform's capabilities, enabling clients to achieve higher levels of customer satisfaction and engagement.

Direct Flow Medical is a medical device company specializing in the development of innovative transcatheter aortic valve replacement systems aimed at treating heart valve diseases. The company's primary focus is on creating a percutaneous aortic tissue valve prosthesis, which offers patients suffering from cardiac valve insufficiency a safe and effective treatment option. With approximately 1.2 million individuals over the age of 65 affected by calcified aortic valves, and only about 150,000 receiving surgical intervention annually, Direct Flow Medical addresses a significant gap in patient care. Their technology allows heart surgeons to conduct repeated assessments of hemodynamic performance prior to final implantation, thereby enhancing patient outcomes and minimizing complications associated with invasive surgeries.

TransCorp Spine manufactures medical devices and procedures to restore spinal function and preserve healthy tissue. Its product includes SpinePort, a MIS access system. David Lowry, Des O'Farrell, and Scott Tuinstra founded TransCorp Spine in 2008. It has its headquarters in Byron Center in Michigan.

Sonoma Orthopedic Products is an orthopedic device company focused on designing, developing, and delivering proprietary orthopedic implants to address complex fractures. Utilizing the WaviBody technology platform, the company provides innovative surgical solutions that are minimally invasive, catering specifically to active patients. The firm specializes in fracture fixation devices that facilitate the repair of challenging bone geometries, enabling orthopedic surgeons to effectively restore function and return patients to their daily activities more rapidly. By prioritizing ease of use and efficacy in their products, Sonoma Orthopedic Products aims to enhance the recovery process for individuals with problematic fractures.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Direct Flow Medical is a medical device company specializing in the development of innovative transcatheter aortic valve replacement systems aimed at treating heart valve diseases. The company's primary focus is on creating a percutaneous aortic tissue valve prosthesis, which offers patients suffering from cardiac valve insufficiency a safe and effective treatment option. With approximately 1.2 million individuals over the age of 65 affected by calcified aortic valves, and only about 150,000 receiving surgical intervention annually, Direct Flow Medical addresses a significant gap in patient care. Their technology allows heart surgeons to conduct repeated assessments of hemodynamic performance prior to final implantation, thereby enhancing patient outcomes and minimizing complications associated with invasive surgeries.

ValenTx, Inc. is a medical device company based in Maple Grove, Minnesota, that specializes in developing innovative therapy solutions for patients suffering from obesity and obesity-related metabolic disorders. Founded in 2002, ValenTx focuses on minimally-invasive treatment methods, including an endoluminal bypass therapy that replicates the anatomical changes of the traditional Roux-en-Y gastric bypass procedure. This technology features an adjustable, removable, and replaceable device designed to address conditions such as type-2 diabetes and hypertension, aiming to improve patient outcomes in the management of these chronic health issues.

Lycera is a preclinical-stage biopharmaceutical company dedicated to developing small molecule immunomodulators aimed at treating autoimmune diseases, including rheumatoid arthritis, lupus erythematosus, and inflammatory bowel disease. The company focuses on creating first-in-class drugs that leverage proprietary technology platforms, including small molecules that modulate a target central to cellular bioenergetics and molecules that target the Th17 pathway. By utilizing ATPase modulators, Lycera’s drug candidates are designed to offer oral efficacy while minimizing the adverse effects associated with conventional antiproliferative and immunosuppressive treatments. Through its innovative approach, Lycera aims to provide effective therapeutic options for patients suffering from various immune-related conditions.

Vontoo is a provider of automated voice messaging tools that enhances one-to-one marketing communication through personalized voice messages. Based in Indianapolis, the company offers a web-based application that allows organizations to create, send, and track tailored voice messages, thereby fostering stronger customer relationships and driving engagement. Vontoo's technology enables users to send automated calls at scale, from a single recipient to millions, facilitating revenue growth, cost reduction, and expedited cash collection. The company is privately owned and has received funding from various sources, including private investors and a venture capital firm.

Perfinity Biosciences, Inc. is a company focused on advancing protein sample preparation through innovative tools and technologies. Founded in 2004 and located in West Lafayette, Indiana, Perfinity offers a diverse product portfolio that includes immobilized enzymes, affinity reagents, optimized buffers, and software solutions. Key products include Soluble Smart Digest, a stable soluble trypsin for efficient digestions; Mag Beads, designed specifically for proteomics; QuicPrep, which integrates immunoaffinity and trypsin digestion in a single tube; and Flash Digest, an immobilized trypsin reactor for reproducible results. The company also provides a Workstation, a multi-column apparatus that automates protein separations and mass spectrometry sample preparation. Perfinity's solutions are tailored to enhance reproducibility and speed across a variety of workflows, including solid tissues, gels, and sample pellets. The company was previously known as QuadraSpec, Inc. before rebranding in March 2010.

HandyLab is a medical technology company that develops and manufactures molecular diagnostic assays and automation platforms The company’s proprietary platform reduces the time, cost, and complexity of testing while improving the quality of results. Using patented real-time microfluidic PCR technology, its products are positioned to decentralize nucleic acid testing. HandyLab was founded in 2000 and is based in Ann Arbor, Michigan. It was acquired by Becton, Dickinson and Company in 2009.

Eleme Medical, Inc. is a venture-backed aesthetics company specializing in advanced technologies for body shaping. The company has developed the SmoothShapes® product line, including the recently launched SmoothShapes® XV, which aims to transform cellulite treatment and enhance pre- and post-liposuction care. This innovative device features 50% more laser power and incorporates audible and visual treatment guidance, all within a portable design, making it suitable for various medical practices. Both SmoothShapes systems leverage the proprietary Photomology® platform, which combines dynamic light and laser energy with mechanical manipulation to effectively address cellulite and subcutaneous fat. These CE Marked and FDA-cleared medical devices are designed to provide long-lasting results that improve the appearance of cellulite. Eleme Medical targets plastic surgeons, aesthetic dermatologists, medical spas, and other aesthetic physicians, positioning itself within a rapidly growing segment of the aesthetics market.

Alure Medical focuses on the development and commercialization of percutaneous soft tissue lift devices and delivery systems for plastic surgery utilizing patent-pending technologies.

Nanosolar, Inc. is a manufacturer of solar electricity cells and panels, specializing in cost-efficient solar solutions. Founded in 2001 and headquartered in San Jose, California, with additional manufacturing facilities in Berlin, Germany, Nanosolar develops innovative products such as the Utility Panel, designed for utility-scale power plants, and SolarPly, a lightweight solar-electric cell foil that can be customized in size. The company's proprietary technology involves printing solar cells using CIGS (Copper, Indium, Gallium, Selenium) and nanoparticle inks, along with an annealing process that reduces reliance on expensive vacuum deposition equipment. By leveraging industrial printing methods and roll-to-roll manufacturing, Nanosolar produces solar-electric foil at high speeds, effectively merging the principles of printing with solar photovoltaic semiconductor production, thereby enhancing economic efficiency in the solar industry.

IntelePeer is a communications automation platform that utilizes generative AI to enhance customer interactions for businesses. By offering a cloud-based Communications Platform as a Service (CPaaS), the company provides on-demand IP communications and SIP trunking services tailored for enterprises. IntelePeer's platform integrates seamlessly with existing systems, allowing businesses to streamline their communication processes across multiple channels. Its focus on automation not only reduces operational costs but also improves customer experience by delivering efficient and effective communication solutions. The incorporation of AI and analytics further enhances the platform's capabilities, enabling clients to achieve higher levels of customer satisfaction and engagement.

Greenplum, Inc. is a data warehousing company that specializes in developing database software designed for business intelligence and data warehousing applications. The company's flagship product, Greenplum Database, is tailored to handle multi-terabyte data warehousing requirements, making it suitable for large-scale data operations. Additionally, Greenplum Network serves as a customer and partner portal, providing instant download access to its database products. The company primarily targets clients in the telecommunications and banking sectors, addressing their specific data management and analytics needs.

Direct Flow Medical is a medical device company specializing in the development of innovative transcatheter aortic valve replacement systems aimed at treating heart valve diseases. The company's primary focus is on creating a percutaneous aortic tissue valve prosthesis, which offers patients suffering from cardiac valve insufficiency a safe and effective treatment option. With approximately 1.2 million individuals over the age of 65 affected by calcified aortic valves, and only about 150,000 receiving surgical intervention annually, Direct Flow Medical addresses a significant gap in patient care. Their technology allows heart surgeons to conduct repeated assessments of hemodynamic performance prior to final implantation, thereby enhancing patient outcomes and minimizing complications associated with invasive surgeries.

RockeTalk is a company focused on enhancing personal communication through its social media platform and mobile applications. It provides users with a variety of multimedia services, allowing them to create and share messages that combine text, voice, photos, and videos. The platform enables users to connect with friends, family, and new acquaintances, join communities, and engage in group chats. By emphasizing safety and an abuse-free environment, RockeTalk verifies user identities through mobile number authentication, ensuring a secure space for interaction. Ultimately, RockeTalk aims to facilitate rich communication and self-expression, connecting people through the diverse media they create and share.

BioSET, Inc., founded in 2001 and based in Rockville, Maryland, specializes in the research and development of synthetic bioactive peptides aimed at enhancing bone and soft tissue repair. The company creates proprietary therapeutic peptides utilized as medical devices in orthobiologics applications. Its notable product, Amplex, is an implantable device that combines a peptide with a synthetic ceramic scaffold, designed for use in spinal fusion surgeries and other orthopedic procedures. Additionally, BioSET develops products for sports medicine and creates peptide signaling molecules along with various scaffold biomaterials for applications in trauma, fracture repair, and soft tissue treatments. As of February 2015, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.

Sonoma Orthopedic Products is an orthopedic device company focused on designing, developing, and delivering proprietary orthopedic implants to address complex fractures. Utilizing the WaviBody technology platform, the company provides innovative surgical solutions that are minimally invasive, catering specifically to active patients. The firm specializes in fracture fixation devices that facilitate the repair of challenging bone geometries, enabling orthopedic surgeons to effectively restore function and return patients to their daily activities more rapidly. By prioritizing ease of use and efficacy in their products, Sonoma Orthopedic Products aims to enhance the recovery process for individuals with problematic fractures.

Sonoma Orthopedic Products is an orthopedic device company focused on designing, developing, and delivering proprietary orthopedic implants to address complex fractures. Utilizing the WaviBody technology platform, the company provides innovative surgical solutions that are minimally invasive, catering specifically to active patients. The firm specializes in fracture fixation devices that facilitate the repair of challenging bone geometries, enabling orthopedic surgeons to effectively restore function and return patients to their daily activities more rapidly. By prioritizing ease of use and efficacy in their products, Sonoma Orthopedic Products aims to enhance the recovery process for individuals with problematic fractures.

Arxan Technologies, Inc. is a leading provider of application protection solutions, specializing in safeguarding critical applications deployed across various platforms, including mobile devices, desktops, and embedded systems in the Internet of Things (IoT). The company offers a range of services designed to protect both source and binary code, enhancing the security perimeter for organizations. Its product lineup includes GuardIT, EnsureIT, TransformIT, and Arxan for Web, which utilize advanced technologies such as code hardening, obfuscation, white-box cryptography, and threat analytics. Arxan's solutions cater to diverse sectors, including financial services, healthcare, automotive, gaming, and e-commerce, and are designed to operate without interfering with software development processes or runtime performance. In addition to its software products, the company provides professional services, including risk assessments and protection design, aimed at ensuring comprehensive security for its clients. Founded in 2001 and headquartered in San Francisco, California, Arxan Technologies has established strategic alliances with notable firms to enhance its offerings.

Greenplum, Inc. is a data warehousing company that specializes in developing database software designed for business intelligence and data warehousing applications. The company's flagship product, Greenplum Database, is tailored to handle multi-terabyte data warehousing requirements, making it suitable for large-scale data operations. Additionally, Greenplum Network serves as a customer and partner portal, providing instant download access to its database products. The company primarily targets clients in the telecommunications and banking sectors, addressing their specific data management and analytics needs.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Lycera is a preclinical-stage biopharmaceutical company dedicated to developing small molecule immunomodulators aimed at treating autoimmune diseases, including rheumatoid arthritis, lupus erythematosus, and inflammatory bowel disease. The company focuses on creating first-in-class drugs that leverage proprietary technology platforms, including small molecules that modulate a target central to cellular bioenergetics and molecules that target the Th17 pathway. By utilizing ATPase modulators, Lycera’s drug candidates are designed to offer oral efficacy while minimizing the adverse effects associated with conventional antiproliferative and immunosuppressive treatments. Through its innovative approach, Lycera aims to provide effective therapeutic options for patients suffering from various immune-related conditions.

ValenTx, Inc. is a medical device company based in Maple Grove, Minnesota, that specializes in developing innovative therapy solutions for patients suffering from obesity and obesity-related metabolic disorders. Founded in 2002, ValenTx focuses on minimally-invasive treatment methods, including an endoluminal bypass therapy that replicates the anatomical changes of the traditional Roux-en-Y gastric bypass procedure. This technology features an adjustable, removable, and replaceable device designed to address conditions such as type-2 diabetes and hypertension, aiming to improve patient outcomes in the management of these chronic health issues.

Greenplum, Inc. is a data warehousing company that specializes in developing database software designed for business intelligence and data warehousing applications. The company's flagship product, Greenplum Database, is tailored to handle multi-terabyte data warehousing requirements, making it suitable for large-scale data operations. Additionally, Greenplum Network serves as a customer and partner portal, providing instant download access to its database products. The company primarily targets clients in the telecommunications and banking sectors, addressing their specific data management and analytics needs.

Direct Flow Medical is a medical device company specializing in the development of innovative transcatheter aortic valve replacement systems aimed at treating heart valve diseases. The company's primary focus is on creating a percutaneous aortic tissue valve prosthesis, which offers patients suffering from cardiac valve insufficiency a safe and effective treatment option. With approximately 1.2 million individuals over the age of 65 affected by calcified aortic valves, and only about 150,000 receiving surgical intervention annually, Direct Flow Medical addresses a significant gap in patient care. Their technology allows heart surgeons to conduct repeated assessments of hemodynamic performance prior to final implantation, thereby enhancing patient outcomes and minimizing complications associated with invasive surgeries.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

BioSET, Inc., founded in 2001 and based in Rockville, Maryland, specializes in the research and development of synthetic bioactive peptides aimed at enhancing bone and soft tissue repair. The company creates proprietary therapeutic peptides utilized as medical devices in orthobiologics applications. Its notable product, Amplex, is an implantable device that combines a peptide with a synthetic ceramic scaffold, designed for use in spinal fusion surgeries and other orthopedic procedures. Additionally, BioSET develops products for sports medicine and creates peptide signaling molecules along with various scaffold biomaterials for applications in trauma, fracture repair, and soft tissue treatments. As of February 2015, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.

Oxand is an independent international consulting and solutions provider specializing in capital-intensive assets. The company delivers risk-informed decision support that enhances returns across the life cycle of clients' assets. Serving a diverse clientele that includes investors, owners, contractors, and managers in sectors such as Energy, Transport, and Public/Private Properties, Oxand has extensive experience in optimizing life cycle decisions and minimizing costs by 10 to 30%. Their expertise allows for life extensions of assets rather than costly renewals, and they effectively reduce delays in large projects. Utilizing their proprietary Simeo™ technologies and comprehensive data libraries, Oxand adheres to best practice standards, including ISO 55000 and ISO 31000. The company provides customized consultancy, training, and IT solutions, ensuring that clients make informed decisions that enhance their reputations and operational efficiency.

HandyLab is a medical technology company that develops and manufactures molecular diagnostic assays and automation platforms The company’s proprietary platform reduces the time, cost, and complexity of testing while improving the quality of results. Using patented real-time microfluidic PCR technology, its products are positioned to decentralize nucleic acid testing. HandyLab was founded in 2000 and is based in Ann Arbor, Michigan. It was acquired by Becton, Dickinson and Company in 2009.

Xtera Communications, Inc. was a provider of optical transport solutions, specializing in Raman amplification-enabled systems for terrestrial and submarine networks. Founded in 1998 and headquartered in Allen, Texas, the company catered to telecommunications service providers, content service providers, enterprises, and government entities globally. Xtera offered a range of products and services, including un-repeatered and repeatered optical systems, designed to enhance network reach and capacity. Its solutions were tailored to meet individual customer needs, encompassing full turnkey systems, open architecture designs, and specific product supply. Despite its previous success in expanding its customer base and product portfolio, Xtera faced financial difficulties that led to its Chapter 11 bankruptcy filing in November 2016, which was later converted to Chapter 7 liquidation in February 2017.

Arxan Technologies, Inc. is a leading provider of application protection solutions, specializing in safeguarding critical applications deployed across various platforms, including mobile devices, desktops, and embedded systems in the Internet of Things (IoT). The company offers a range of services designed to protect both source and binary code, enhancing the security perimeter for organizations. Its product lineup includes GuardIT, EnsureIT, TransformIT, and Arxan for Web, which utilize advanced technologies such as code hardening, obfuscation, white-box cryptography, and threat analytics. Arxan's solutions cater to diverse sectors, including financial services, healthcare, automotive, gaming, and e-commerce, and are designed to operate without interfering with software development processes or runtime performance. In addition to its software products, the company provides professional services, including risk assessments and protection design, aimed at ensuring comprehensive security for its clients. Founded in 2001 and headquartered in San Francisco, California, Arxan Technologies has established strategic alliances with notable firms to enhance its offerings.

Arbor Networks specializes in securing complex networks against DDoS attacks and advanced threats. The company offers a suite of products that provides customers with detailed insights into their own networks while also leveraging its ATLAS threat intelligence infrastructure for a broader understanding of global Internet traffic and emerging threats. With contributions from over 330 service providers generating 120 Tbps of traffic intelligence, Arbor's Security Engineering & Response Team develops protective measures that are integrated into customer products to combat DDoS and malware threats. Arbor's DDoS Solutions are adaptable, catering to various deployment needs, including virtual solutions, network-embedded systems, and enterprise appliances. The Arbor Cloud service combines on-premises and cloud-based mitigation for comprehensive DDoS defense. Additionally, Arbor Advanced Threat Solutions utilize integrated Netflow and Packet Capture technology to enhance network-wide situational awareness and provide deep traffic visibility, enabling effective threat detection and response through real-time insights and historical analysis. The company's focus is on ensuring the availability of critical infrastructure while safeguarding against advanced threats.

HandyLab is a medical technology company that develops and manufactures molecular diagnostic assays and automation platforms The company’s proprietary platform reduces the time, cost, and complexity of testing while improving the quality of results. Using patented real-time microfluidic PCR technology, its products are positioned to decentralize nucleic acid testing. HandyLab was founded in 2000 and is based in Ann Arbor, Michigan. It was acquired by Becton, Dickinson and Company in 2009.

Virtual Silicon Technology is a provider of SIP solutions to manufacturers and designers of system-on-chip semiconductors.

Xtera Communications, Inc. was a provider of optical transport solutions, specializing in Raman amplification-enabled systems for terrestrial and submarine networks. Founded in 1998 and headquartered in Allen, Texas, the company catered to telecommunications service providers, content service providers, enterprises, and government entities globally. Xtera offered a range of products and services, including un-repeatered and repeatered optical systems, designed to enhance network reach and capacity. Its solutions were tailored to meet individual customer needs, encompassing full turnkey systems, open architecture designs, and specific product supply. Despite its previous success in expanding its customer base and product portfolio, Xtera faced financial difficulties that led to its Chapter 11 bankruptcy filing in November 2016, which was later converted to Chapter 7 liquidation in February 2017.

MetaMatrix is an U.S.-based technology company that created the first true Enterprise Information Integration (EII) software product.

IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.

Ican Inc., is a provider of Internet-based information and tools for health professionals.

Ican provides Internet-based information and tools for health professionals.

Alfalight is a designer and manufacturer of high-power diode lasers, serving the industrial, defense, and telecommunications sectors. The company specializes in a range of laser and electro-optical systems, including precision lasers that operate in the short-wave infrared, near infrared, and visible spectra. Alfalight's technology is distinguished by its innovative aluminum-free active region (ALFA) laser structures, which allow for the production of laser diodes that exhibit exceptional reliability and efficiency, positioning the company as a leader in the laser technology market.

Centromine offers a browser-based, internet-accessed, enterprise-wide software applications and services for the health care market. Its applications allow behavioral health care programs and providers to manage the delivery and associated quality and cost of services completely over the internet.

IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.

Pixelworks, Inc. is a semiconductor and software company that specializes in video and pixel processing solutions for high-end display applications. Founded in 1997 and headquartered in San Jose, California, Pixelworks designs and markets a range of products including image processor integrated circuits (ICs), video co-processor ICs, and transcoder ICs. These products are utilized in various devices such as smartphones, tablets, projectors, and digital signage, facilitating high-quality video experiences across multiple formats and sources. The company leverages its proprietary technologies to help manufacturers enhance their display products while also enabling rapid development and customization to reduce time to market. Pixelworks maintains an extensive intellectual property portfolio, holding numerous patents related to the visual display of digital images, underscoring its commitment to innovation in the visual processing sector. The company sells its solutions through a direct sales force, as well as distributors and manufacturers’ representatives globally.

IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.